Prevalence and Risk Factors for Non-Vertebral Fractures in Patients Receiving Oral Glucocorticoids

AUTHORS

Sosa-HenrIquez Manuel 1 , * , Gomez de Tejada-Romero Maria Jesus 2 , Saavedra-Santana Pedro 2 , Blazquez-Cabrera Jose Antonio 2 , Garcia-Vadillo Jess Alberto 2 , Valdes-Llorca Carmen 2 , Diaz-Curiel Manuel 2 , Munoz-Torres Manuel 2 , Martinez-Rodriguez Maria Elena 2 , Navarro-Ceballos Carmen 2 , Sanfelix-Genoves Jose 2 , Cancelo-Hidalgo Maria Jesus 2 , Carpintero-Benitez Pedro 2 , Mesa-Ramos Manuel 2 , Palacios-Gil Antunano 3

1 Spanish Society for Investigation of Osteoporosis and Bone Metabolic Diseases (SEIOMM), Spain

2 Spanish Society for Investigation of Osteoporosis and Bone Metabolic Diseases (SEIOMM), [email protected], Spain

3 Santiago, International Society of Osteoporosis and Bone Mineral Metabolism (SIBOMM), Madrid

How to Cite: Manuel S, Jesus G D T M, Pedro S, Jose Antonio B, Alberto G J, et al. Prevalence and Risk Factors for Non-Vertebral Fractures in Patients Receiving Oral Glucocorticoids, Int J Endocrinol Metab. Online ahead of Print ; 10(2):480-485. doi: 10.5812/ijem.3442.

ARTICLE INFORMATION

International Journal of Endocrinology and Metabolism: 10 (2); 480-485
Published Online: December 1, 2012
Article Type: Original Article
Received: November 7, 2011
Accepted: March 2, 2012
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Glucocorticoids taken orally increase the risk of fractures. It has been noted that a dose as low as 2.5 mg/day increases the risk of vertebral fracture. What is less clear is the possible influence of other risk factors for osteoporosis on the presence of non-vertebral fractures in patients taking glucocorticoids.

Objectives: A cross-sectional study, performed on 513 men and women from Spain, who were taking at least 7.5 mg/day of oral prednisone for a minimum of 3 months. A questionnaire was developed, through which information on risk factors was collected.

Patients and Methods: A cross-sectional study, performed on 513 men and women from Spain, who were taking at least 7.5 mg/day of oral prednisone for a minimum of 3 months. A questionnaire was developed, through which information on risk factors was collected.

Results: 28.3% of the patients who were taking glucocorticoids at a daily oral dose of 7.5 mg/day for a minimum of 3 months had suffered at least one non-vertebral fracture. The risk increased with age, the number of months the glucocorticoids had been taken, the presence of falls in the last year and, above all, with a maternal history of hip fracture.

Conclusions: In patients taking oral glucocorticoids for over 3 months at doses higher than 7.5 mg/day of prednisone or equivalent, the prevalence of non-vertebral fractures was 28.3%. Some risk factors associated with the presence of these fractures were identified. The duration of glucocorticoid use appears to be more strongly related to the presence of non-vertebral fractures than the daily dose.

Keywords

© 2012, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: